Title of article
QT Interval Prolongation in COVID-19 Patients on Methadone Treatment
Author/Authors
Sefidgarnia, Maryam Department of Psychiatry - Psychiatry and Behavioral Sciences Research Center - Addiction Institute - Mazandaran University of Medical Sciences, Sari , Salari, Susan Mazandaran University of Medical Sciences, Sari , Alaedini, Kamaledin Mazandaran University of Medical Sciences, Sari
Pages
2
From page
1
To page
2
Abstract
As a result of a widespread infection named coronavirus
disease 2019 (COVID-19), there has been a critical request
in the world for medications. Up to now, there are no
proved effective therapeutic medicines for COVID-19. New
medicines and immunizations will take time to be developed
and disseminated to patients. Because of variables
such as the history of prescription for other infectious diseases,
availability, and relatively low cost (1), there has been
increasing intrigue about the use of existing medications
such as chloroquine (CQ) and hydroxychloroquine (HCQ)
as potential treatments for this disease (2) or prophylaxis
against COVID-19 (3). For instance, some overviews indicate
that hydroxychloroquine is significantly associated
with viral load reduction/disappearance in patients with
COVID-19, and its impact is fortified by azithromycin (4).
Keywords
COVID-19 , Methadone , QT Interval
Journal title
Iranian Journal of Psychiatry and Behavioral Sciences (IJPBS)
Serial Year
2020
Record number
2519391
Link To Document